Guided by Leaders with a Strong Track Record of Execution
Comprised of leaders from academia, life science companies, and emerging biotechs, our team shares a deep connection to the rare epilepsy community and a passion for changing the way epileptic drugs are discovered and developed.
Darren Cline, MBA
President and Chief Executive Officer
Darren most recently served as the U.S. Chief Commercial Officer of GW Pharmaceuticals, where he was responsible for all commercial and medical affairs activities associated with Epidiolex prior to GW’s acquisition by Jazz Pharmaceuticals for $7.2 billion in 2021. Previously, he was Seagen’s Executive Vice President, Commercial, participating in the management of all aspects of Seagen’s operations and accountable for Seagen’s commercialization of Adcetris . Prior to Seagen, Darren had key commercial leadership roles at Intermune, Alexion and Amgen. He is currently a member of the Pyxis Oncology Board of Directors and was formerly on the Stemline Therapeutics Board of Directors. Darren received his undergraduate degrees in marketing from San Diego State University and his Master of Business Administration from Pepperdine University.
Lorianne Masuoka, MD
Chief Medical Officer
Dr. Masuoka has more than 25 years of experience building and expanding high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances. She is a board-certified neurologist who has successfully created and overseen high performing teams to lead the clinical development of new medicines, with a focus in multiple sclerosis, oncology, and epilepsy. Dr. Masuoka served as Chief Medical Officer of Marinus Pharmaceuticals, Cubist Pharmaceuticals (now Merck), and Nektar Therapeutics where, as a member of executive management, she managed teams in the areas of clinical research, pharmacovigilance, biostatistics and data management, regulatory affairs, and clinical operations. Previously, she held various roles of increasing responsibility at FivePrime Therapeutics (now Amgen) and Chiron (now Novartis). In addition to her executive roles, Dr. Masuoka most recently served as a Board member at Pfenex Inc. (now Ligand) and serves as a Board member at Opiant Pharmaceuticals.
Dr. Masuoka received her medical degree from the University of California, Davis, where she also completed her residency in neurology. She completed her epilepsy fellowship at Yale University and is board certified by the American Board of Psychiatry and Neurology.
G. Michael Landis, CPA
Chief Financial Officer
Michael is a highly accomplished financial executive who brings an over 25-year track record of public company expertise, capital market transactions, investor relations, and financial reporting. Prior to joining Epygenix, Michael was most recently the Chief Financial Officer at Avisa Diagnostics Inc., a publicly traded medical device company. While there, he was responsible for strategic and tactical finance initiatives and was directly involved with investor relations and capital raising activities. Before that, he served as Principal Accounting Officer and Treasurer at Lannett Company Inc., a publicly traded pharmaceutical company, where he led acquisitions and related financing activities and was a member of the executive team that successfully completed a $1.2 billion acquisition. Michael was also actively involved in the initial Public Offering (IPO) process in previous financial leadership roles at companies including Akrion Inc. and AlliedBarton Security Services, LLC. Earlier, he worked at various other publicly traded companies after beginning his career within the Big Four public accounting firms. Michael received his Bachelors in Accounting from Franklin & Marshall College and is an active Certified Public Accountant.